Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: A cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 4, 2010, Pages 741-748

  Ghosn, Jade ^a,b   Deveau, Christiane ^b,c   Chaix, Marie Laure ^a   Goujard, Cécile ^b,c   Galimand, Julie ^a   Zitoun, Yasmine ^b,c   Allègre, Thierry ^d   Delfraissy, Jean François ^b,c   Meyer, Laurence ^b,c   Rouzioux, Christine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICÊTRE HOSPITAL   (France)

^c INSERM   (France)

^d CHR du Pays d'Aix   (France)

Author keywords

CD4 cell count; Clinical symptoms; Diversity; HIV; HIV DNA; HIV RNA; Primary infection

Indexed keywords

CD4 ANTIGEN; VIRUS DNA; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; WESTERN BLOTTING; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; VIROLOGY;

ADOLESCENT; ADULT; AGED; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; YOUNG ADULT;

EID: 77952580564     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq035     Document Type: Article

References (32)

1. Schacker T, Collier AC, Hughes J et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125: 257-64.
2. Lievre L, Deveau C, Gerbe J et al. Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach. AIDS 2006; 20: 2392-5.
3. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-9.
4. Daar ES, Little S, Pitt J et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001; 134:25-9.
5. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000; 355: 1131-7.
6. Vanhems P, Hirschel B, Phillips AN et al. Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. J Infect Dis 2000; 182: 334-7.
7. Mellors JW, Rinaldo CR Jr, Gupta P et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.
8. Henrard DR, Daar E, Farzadegan H et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 305-10.
9. Boufassa F, Bachmeyer C, Carre N et al. Influence of neurologic manifestations of primary human immunodeficiency virus infection on disease progression. SEROCO Study Group. J Infect Dis 1995; 171: 1190-5.
10. Little SJ, McLean AR, Spina CA et al. Viral dynamics of acute HIV-1 infection. J Exp Med 1999; 190: 841-50.
11. Schacker TW, Hughes JP, Shea T et al. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-20.
12. Hubert JB, Burgard M, Dussaix E et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS 2000; 14: 123-31.
13. Touloumi G, Pantazis N, Babiker AG et al. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS 2004; 18: 1697-705.
14. Goujard C, Bonarek M, Meyer L et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42: 709-15.
15. Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 2007; 45: 445-8.
16. Vanhems P, Lambert J, Cooper DA et al. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 1998; 26: 323-9.
17. Chaix ML, Descamps D, Harzic M et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003; 17: 2635-43.
18. Desquilbet L, Goujard C, Rouzioux C et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004; 18: 2361-9.
19. Ghosn J, Pellegrin I, Goujard C et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20: 159-70.
20. Adalid-Peralta L, Godot V, Colin C et al. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection. J Leukoc Biol 2008; 83: 1060-7.
21. Avettand-Fenoel V, Chaix ML, Blanche S et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009; 81: 217-23.
22. Rouet F, Ekouevi DK, Chaix ML et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005; 43: 2709-17.
23. Rouzioux C, Hubert JB, Burgard M et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005; 192: 46-55.
24. Kostrikis LG, Touloumi G, Karanicolas R et al. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002; 76: 10099-108.
25. Descamps D, Chaix ML, Andre P et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38: 545-52.
26. PHYLIP, Phylogeny Inference Package, version 3.6 (alpha) (computer program). Seattle, WA: Department of Genetics, University of Washington, 2001.
27. Chun TW, Engel D, Berrey MM et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95: 8869-73.
28. Schacker T, Little S, Connick E et al. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis 2000; 181: 354-7.
29. Hubert JB, Rouzioux C, Seng R et al. HIV-RNA and HIV-DNA levels measured soon after seroconversion and variability in subsequent CD4 cell decline. Paper Presented at the Twelfth International Workshop on HIV Observational Databases, Malaga, Spain, 2008. Abstract 72.
30. Chaix ML, Desquilbet L, Descamps D et al. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther 2007; 12: 1305-10.
31. Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.
32. Yeni PG. Prise en charge médicale des personnes infectées par le VIH. Paris, 2008.